- Home
- RRGB vs ZNTL Comparison
RRGB vs ZNTL Comparison
Compare RRGB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- ZNTL
- Stock Information
- Founded
- RRGB 1969
- ZNTL 2014
- Country
- RRGB United States
- ZNTL United States
- Employees
- RRGB N/A
- ZNTL N/A
- Industry
- RRGB Restaurants
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- RRGB Consumer Discretionary
- ZNTL Health Care
- Exchange
- RRGB Nasdaq
- ZNTL Nasdaq
- Market Cap
- RRGB 88.7M
- ZNTL 105.8M
- IPO Year
- RRGB 2002
- ZNTL 2020
- Fundamental
- Price
- RRGB $6.81
- ZNTL $1.42
- Analyst Decision
- RRGB Strong Buy
- ZNTL Buy
- Analyst Count
- RRGB 2
- ZNTL 7
- Target Price
- RRGB $11.00
- ZNTL $8.46
- AVG Volume (30 Days)
- RRGB 259.8K
- ZNTL 793.4K
- Earning Date
- RRGB 11-05-2025
- ZNTL 11-11-2025
- Dividend Yield
- RRGB N/A
- ZNTL N/A
- EPS Growth
- RRGB N/A
- ZNTL N/A
- EPS
- RRGB N/A
- ZNTL N/A
- Revenue
- RRGB $1,235,920,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- RRGB N/A
- ZNTL N/A
- Revenue Next Year
- RRGB N/A
- ZNTL N/A
- P/E Ratio
- RRGB N/A
- ZNTL N/A
- Revenue Growth
- RRGB N/A
- ZNTL N/A
- 52 Week Low
- RRGB $2.50
- ZNTL $1.01
- 52 Week High
- RRGB $7.89
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- RRGB 61.14
- ZNTL 39.87
- Support Level
- RRGB $5.98
- ZNTL $1.60
- Resistance Level
- RRGB $7.01
- ZNTL $2.02
- Average True Range (ATR)
- RRGB 0.27
- ZNTL 0.12
- MACD
- RRGB 0.04
- ZNTL -0.05
- Stochastic Oscillator
- RRGB 80.58
- ZNTL 3.23
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.